EP Patent

EP3688161A1 — Compositions and methods for ttr gene editing and treating attr amyloidosis

Assigned to Intellia Therapeutics Inc · Expires 2020-08-05 · 6y expired

What this patent protects

Compositions and methods for editing, e.g., introducing double-stranded breaks, within the TTR gene are provided. Compositions and methods for treating subjects having amyloidosis associated with transthyretin (ATTR), are provided.

USPTO Abstract

Compositions and methods for editing, e.g., introducing double-stranded breaks, within the TTR gene are provided. Compositions and methods for treating subjects having amyloidosis associated with transthyretin (ATTR), are provided.

Drugs covered by this patent

Patent Metadata

Patent number
EP3688161A1
Jurisdiction
EP
Classification
—
Expires
2020-08-05
Drug substance claim
No
Drug product claim
No
Assignee
Intellia Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.